Marie T. Leccia
Rennes, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Four years of study by an expert group on truncal acne: where are we now?
Journal: European journal of dermatology : EJD
Published: March 20, 2025
Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort.
Journal: Melanoma research
Published: November 11, 2024
Efficacy of imiquimod in the management of lentigo maligna.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: December 30, 2022
Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic Melanoma.
Journal: Cancers
Published: May 18, 2021
Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study.
Journal: International journal of cancer
Published: August 20, 2020
Deep cutaneous fungal infections in solid-organ transplant recipients.
Journal: Journal of the American Academy of Dermatology
Published: July 16, 2019
Bradykinin mechanism is the main responsible for death by isolated asphyxiating angioedema in France.
Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: February 21, 2018
Cutaneous Collagenous Vasculopathy: Report of Two Cases Presenting as Disseminated Telangiectasias and Review of the Literature.
Journal: The American Journal of dermatopathology
Published: June 14, 2017
Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications.
Journal: BioMed research international
Published: August 11, 2016
Identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma.
Journal: JAMA dermatology
Published: October 11, 2013
Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 07, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026